Eijiro Horisawa

436 citations
11 papers · 365 indexed · h-index 9
Topics
Drug Solubulity and Delivery Systems (7 papers)Advancements in Transdermal Drug Delivery (3 papers)Advanced Drug Delivery Systems (3 papers)
Partner nations
Japan

In The Last Decade

Eijiro Horisawa

11 papers receiving 356 citations

Peers

Eijiro Horisawa
Comparison fields: 5 of 74
  • Pharmaceutical Science 185
  • Rheumatology 105
  • Biomaterials 68
  • Molecular Biology 62
  • Food Science 34
Replace Xingli Zhou with:
Xingli Zhou China
Tongfei Shi China
Andreia Marinho Portugal
Liling Mei China
Dieter Gebauer Germany
Xinxin Yu China
P. Arunkumar India
Solange A. Valdes United States
Joon‐Ho Bae South Korea
Susan C. Pankey United States
Eijiro Horisawa relative to Xingli Zhou China Xingli Zhou's profile →
Citations per field
00.5×10×13×
Xingli Zhou · 1×
Citations per year

Countries citing papers authored by Eijiro Horisawa

Since Specialization
Citations

This map shows the geographic impact of Eijiro Horisawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eijiro Horisawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eijiro Horisawa more than expected).

Fields of papers citing papers by Eijiro Horisawa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eijiro Horisawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eijiro Horisawa. The network helps show where Eijiro Horisawa may publish in the future.

Co-authorship network of co-authors of Eijiro Horisawa

This figure shows the co-authorship network connecting the top 25 collaborators of Eijiro Horisawa. A scholar is included among the top collaborators of Eijiro Horisawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eijiro Horisawa. Eijiro Horisawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
#WorkIndexed citations
1 6
2 2
3 8
4 147
5 112
6 31
7 13
8 10
9 16
10 10
11 10

About Eijiro Horisawa

Eijiro Horisawa is a scholar working on Pharmaceutical Science, Analytical Chemistry and Food Science, having authored 11 papers that have together received 365 indexed citations. Recurring topics across this work include Drug Solubulity and Delivery Systems (7 papers), Advancements in Transdermal Drug Delivery (3 papers) and Advanced Drug Delivery Systems (3 papers). The work is most often cited by research in Pharmaceutical Science (185 citations), Rheumatology (105 citations) and Biomaterials (68 citations). Eijiro Horisawa has collaborated with scholars based in Japan. Frequent co-authors include Hirofumi Takeuchi, Yoshiaki Kawashimà, Hiromitsu Yamamoto, Kazumi Danjo, Jun Yamada, Akinobu OTSUKA, Hisakazu Sunada, Mitsumasa Haruna, Yuki Ashizuka and Kotaro Iida. Their work appears in journals such as Pharmaceutical Research, Chemical and Pharmaceutical Bulletin and Drug Development and Industrial Pharmacy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026